NCT03254667
LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
Enrolling by Invitation
Not specifiedAges 18–99ObservationalBausch Health Americas, Inc.
~3,500 participants
Updated 2025-09-16 on ClinicalTrials.gov
What's tested:BrodalumabComparator Drug (non-biologic IL-17 inhibitors)
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Assess the incidence of malignancy
Measured over 8 years
Conditions
Where it's being run
1 sites across 1 statesNew Jersey1
Study leadership
- Varsha Bhatt · STUDY_DIRECTOR · Bausch Health Americas, Inc.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Assess the incidence of malignancy8 years
Assess the incidence of malignancy, excluding non-melanoma skin cancer (NMSC), in adult psoriasis subjects exposed to brodalumab in the course of actual clinical care compared to non-IL-17-inhibitor biologic medications used to treat psoriasis.